{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:19:01Z","timestamp":1762867141621,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:00:00Z","timestamp":1496793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Down\u2019s syndrome (DS), the most common genetic cause of significant intellectual disability in children and adults is caused by the trisomy of either all or a part of human chromosome 21 (HSA21). Patients with DS mostly suffer from characteristic tumor types. Although individual patients of DS are at a higher risk for acute leukemia and testicular cancers, other types of solid tumors including breast cancers are mostly uncommon and have significantly lower-than-expected age-adjusted incidence rates. Except for an increased risk of retinoblastomas, and lymphomas, the risk of developing solid tumors has been found to be lower in both children and adults, and breast cancer was found to be almost absent (Hasle H., The Lancet Oncology, 2001). A study conducted in the United States found only one death when 11.65 were expected (Scholl T et al., Dev Med Child Neurol. 1982). A recent study examined mammogram reports of women with DS treated in the largest medical facility specifically serving adults with DS in the United States. It was found that only 0.7% women with DS had been diagnosed with breast cancers (Chicoine B et al., Intellect Dev Disabil. 2015). Here we describe a case of breast cancer in a 25-year-old patient with DS. The disease was presented as lymph node positive carcinoma with alterations of tumor suppressor genes characteristic to the triple negative breast cancer subtype. Comprehensive Genomic Profiling (CGP) revealed a wild-type status for BRCA1. The CGP report showed a frameshift mutation, A359fs*10 of the tumor suppressor gene INPP4B and another frameshift mutation, R282fs*63 of tumor suppressor gene TP53 in the tumor biopsy as characteristically found in triple-negative breast cancers. The VUS (Variance of Unknown Significance) alteration(s) were identified in ASXL1 (L1395V), NTRK1 (G18E), DDR2 (I159T), RUNX1 (amplification), ERG (amplification), SOX2 (T26A), FAM123B (G1031D), and HNF1A (A301T). Bonafide cancer-related genes of chromosome 21 amplified in the patient\u2019s tumor are RUNX1 and ERG genes. After the completion of the radiation, the patient was placed on everolimus which was based on the result of her CGP report. Thus, post-mastectomy radiation therapy was completed with a recommendation for everolimus for one year. During the time of writing of this report, no metastatic lesions were identified. The patient currently has no evidence of disease.<\/jats:p>","DOI":"10.3390\/ijms18061218","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T10:01:20Z","timestamp":1496829680000},"page":"1218","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Down\u2019s Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship"],"prefix":"10.3390","volume":"18","author":[{"given":"Nandini","family":"Dey","sequence":"first","affiliation":[{"name":"Center for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA"},{"name":"Departmental of Internal Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD 57105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Krie","sequence":"additional","affiliation":[{"name":"Center for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Klein","sequence":"additional","affiliation":[{"name":"Center for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirstin","family":"Williams","sequence":"additional","affiliation":[{"name":"Center for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"McMillan","sequence":"additional","affiliation":[{"name":"Center for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Elsey","sequence":"additional","affiliation":[{"name":"Center for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuliang","family":"Sun","sequence":"additional","affiliation":[{"name":"Center for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey","family":"Williams","sequence":"additional","affiliation":[{"name":"Center for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA"},{"name":"Departmental of Internal Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD 57105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradip","family":"De","sequence":"additional","affiliation":[{"name":"Center for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA"},{"name":"Departmental of Internal Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD 57105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-0774","authenticated-orcid":false,"given":"Brian","family":"Leyland-Jones","sequence":"additional","affiliation":[{"name":"Center for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2353\/jmoldx.2009.080132","article-title":"Down syndrome and malignancies: A unique clinical relationship: A paper from the 2008 william beaumont hospital symposium on molecular pathology","volume":"11","author":"Xavier","year":"2009","journal-title":"J. Mol. Diagn."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/13816810500228894","article-title":"Association Down syndrome-retinoblastoma: A new observation","volume":"26","author":"Satge","year":"2005","journal-title":"Ophthalmic Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/01.COC.0000018298.72379.AC","article-title":"Three cases of advanced seminoma and Down\u2019s syndrome: A possible association","volume":"26","author":"Vaughn","year":"2003","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S0344-0338(96)80165-8","article-title":"A case report of Down syndrome and centroblastic lymphoma","volume":"192","author":"Satge","year":"1996","journal-title":"Pathol Res. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1365-2788.2001.00322.x","article-title":"Cancer incidence among people with intellectual disability","volume":"45","author":"Patja","year":"2001","journal-title":"J. Intellect. Disabil. Res."},{"key":"ref_6","first-page":"1239","article-title":"Breast cancer in women with trisomy 21","volume":"185","author":"Satge","year":"2001","journal-title":"Bull. Acad Natl Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1469-8749.1982.tb13702.x","article-title":"Leukemia and other cancers, anomalies and infections as causes of death in Down\u2019s syndrome in the United States during 1976","volume":"24","author":"Scholl","year":"1982","journal-title":"Dev. Med. Child. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1352\/1934-9556-53.2.91","article-title":"Breast cancer screening for women with Down syndrome: Lessons learned","volume":"53","author":"Chicoine","year":"2015","journal-title":"Intellect Dev. Disabil."},{"key":"ref_9","first-page":"211","article-title":"Trisomy 21 and breast cancer: A genetic abnormality which protects against breast cancer?","volume":"44","author":"Cordier","year":"2016","journal-title":"Gynecol. Obstet Fertil."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"12031","DOI":"10.1073\/pnas.0813248106","article-title":"The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies","volume":"106","author":"Korbel","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"(2016). Bursts of chromosome changes drive TNBC. Cancer Discov., 6, 1075.","DOI":"10.1158\/2159-8290.CD-NB2016-110"},{"key":"ref_12","first-page":"749","article-title":"Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers","volume":"9","author":"Pfefferle","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.2174\/138945012803530116","article-title":"Targeting basal-like breast cancers","volume":"13","author":"Dey","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490, 61\u201370.","DOI":"10.1038\/nature11412"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/2159-8290.CD-12-0462","article-title":"The genomic landscape of breast cancer as a therapeutic roadmap","volume":"3","author":"Ellis","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"22231","DOI":"10.1073\/pnas.1015245107","article-title":"Inositol polyphosphate 4-phosphatase II regulates PI3K\/Akt signaling and is lost in human basal-like breast cancers","volume":"107","author":"Fedele","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","unstructured":"Teicher, B.A. (2016). PI3K-AKT-mTOR Pathway Cooperates with the DNA Damage Repair Pathway: Carcinogenesis in Triple-Negative Breast Cancers and Beyond, Springer."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Dey, N., De, P., and Leyland-Jones, B. (2017). PI3K\u2013AKT\u2013mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. Pharmacol. Ther.","DOI":"10.1016\/j.pharmthera.2017.02.037"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"De, P., Dey, N., and Leyland-Jones, B. (2013). Growth factor and signaling networks. Brenner\u2019s Encyclopedia of Genetics, Elsevier.","DOI":"10.1016\/B978-0-12-374984-0.00664-1"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/35012518","article-title":"The DNA sequence of human chromosome 21","volume":"405","author":"Hattori","year":"2000","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.4161\/cc.10.20.18029","article-title":"RUNX1 and its understudied role in breast cancer","volume":"10","author":"Janes","year":"2011","journal-title":"Cell Cycle"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/jcp.24989","article-title":"RUNX1 is associated with breast cancer progression in MMTV\u2013PyMT transgenic mice and its depletion in vitro inhibits migration and invasion","volume":"230","author":"Browne","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ferrari, N., Mohammed, Z.M., Nixon, C., Mason, S.M., Mallon, E., McMillan, D.C., Morris, J.S., Cameron, E.R., Edwards, J., and Blyth, K. (2014). Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100759"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bbagrm.2016.08.003","article-title":"RUNX1 contributes to higher-order chromatin organization and gene regulation in breast cancer cells","volume":"1859","author":"Barutcu","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/15384101.2016.1237325","article-title":"Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive breast cancer","volume":"16","author":"Chimge","year":"2017","journal-title":"Cell Cycle"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Dey, N., Barwick, B.G., Moreno, C.S., Ordanic-Kodani, M., Chen, Z., Oprea-Ilies, G., Tang, W., Catzavelos, C., Kerstann, K.F., and Sledge, G.W. (2013). Wnt signaling in triple negative breast cancer is associated with metastasis. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-537"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Dey, N., Young, B., Abramovitz, M., Bouzyk, M., Barwick, B., and De, P. (2013). Differential activation of Wnt-\u03b2-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0077425"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.18632\/oncotarget.13618","article-title":"RAC1 GTP-ase signals Wnt-\u03b2-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers","volume":"8","author":"De","year":"2017","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"43124","DOI":"10.18632\/oncotarget.8988","article-title":"Wnt-\u03b2-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers","volume":"7","author":"De","year":"2016","journal-title":"Oncotarget"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/6\/1218\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:38:14Z","timestamp":1760207894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/6\/1218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,7]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6]]}},"alternative-id":["ijms18061218"],"URL":"https:\/\/doi.org\/10.3390\/ijms18061218","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2017,6,7]]}}}